Understanding cardiogenic shock in patients admitted to intensive care
Official title: Pharmacological and Mechanical Support Approaches in the Management of Acute Heart Failure in the Regional Network Model for the Management of Cardiogenic Shock
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06827314 · Data updated 2026-11-12
This study looks at how common cardiogenic shock is in patients in intensive care and what happens to them based on their age, sex, and the cause of their condition.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, Bologna) |
| Status | Recruiting |
| Started | December 6, 2022 |
| Main results expected | November 2027 |
| Study ends | November 2027 |
| Registry record updated | February 14, 2025 |
| Trial ID | NCT06827314 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adult patients aged 18 and older who are admitted to a cardiac intensive care unit with suspected cardiogenic shock.
✕Probably not a fit
Patients who have experienced cardiogenic shock following cardiac surgery or those with significant polytrauma or neurological injuries may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to describe the epidemiology of cardiogenic shock in the Emilia Romagna region, focusing on outcomes based on different causes, sex, and age. It will analyze the incidence of cardiogenic shock among cardiac intensive care unit admissions, in-hospital mortality rates, and length of hospital stays. The study will include both retrospective and prospective cohorts of patients diagnosed with cardiogenic shock, with data collected on their demographics, treatment strategies, and clinical outcomes. Patients will receive standard care as determined by their physicians, with no experimental interventions involved.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the management and outcomes of cardiogenic shock, potentially improving patient care strategies.
How similar studies have gone: While this study is observational and focuses on epidemiology, similar studies have provided valuable data on cardiogenic shock management, suggesting that understanding this condition can lead to improved outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (≥18 years old) admitted to a participating CICU with suspected CS of stage from C to E according to SCAI (Society of cardiovascular intervention)classification of cardiogenic shock. * Signed informed consent. Exclusion Criteria: * CS following cardiac surgery (post-cardiotomy), ● Significant polytrauma or neurological injury.
Where it's running
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy Recruiting
Study contacts
- Principal investigator: Luciano G Potena, MD — IRCCS Azienda Ospedaliero-Universitaria di Bologna
- Study coordinator: Luciano Potena, MD
- Email: scompenso.trapiantocuore@aosp.bo.it
- Phone: 0512143725
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Factors Influencing Outcomes in ECMO and Impella Patients
This study tests whether metabolic and thyroid hormone changes help predict survival for adults on ECMO or Impella at a single Hungarian cardiac ICU.
-
Evaluating a noninvasive tissue sensor to detect cardiogenic shock earlier in heart patients
This pilot, noninvasive study tests whether the NIRSense wearable can help detect deterioration in adults with cardiogenic shock risk due to heart attack or heart failure.
-
Safety and Efficacy of an Extracorporeal Ventricular Assist System for Cardiogenic Shock
This study tests whether an extracorporeal ventricular assist device can safely provide short-term heart support and help patients with cardiogenic shock or trouble weaning from bypass.
-
Left Ventricular Support and Advanced Monitoring in AMI–Cardiogenic Shock: Immediate Impella Use and PAC/Monitoring vs Standard Care
In adults with heart attack-related cardiogenic shock, this trial tests whether using an Impella left ventricular assist device and/or protocolized pulmonary artery catheter monitoring improves survival compared with standard care.
-
CRP Apheresis for infarct-related cardiogenic shock
This study tests whether selectively removing C-reactive protein with apheresis, in addition to standard care, helps people with cardiogenic shock after a heart attack.
-
Compare two ventilator modes in adults with cardiac ICU needs and invasive ventilation
This pilot tests whether volume-controlled versus pressure-controlled ventilation can be safely used in adults with heart disease and respiratory failure who need invasive ventilation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.